Cargando…
Effect of Food on the Pharmacokinetic Profile of Etamicastat (BIA 5-453)
Background: Etamicastat is a novel, potent, and reversible peripheral dopamine-β-hydroxylase inhibitor that has been administered orally at doses up to 600mg once daily for 10 days to male healthy volunteers and appears to be well tolerated. Objective: The aim of this study was to investigate the ef...
Autores principales: | Vaz-da-Silva, Manuel, Nunes, Teresa, Rocha, José F., Falcão, Amilcar, Almeida, Luis, Soares-da-Silval, Patricio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3585837/ https://www.ncbi.nlm.nih.gov/pubmed/21548660 http://dx.doi.org/10.2165/11587080-000000000-00000 |
Ejemplares similares
-
Safety, Tolerability, and Pharmacokinetics of Etamicastat, a Novel Dopamine-β-Hydroxylase Inhibitor, in a Rising Multiple-Dose Study in Young Healthy Subjects
por: Nunes, Teresa, et al.
Publicado: (2012) -
Safety, Tolerability, and Pharmacokinetics of FAAH Inhibitor BIA 10‐2474: A Double‐Blind, Randomized, Placebo‐Controlled Study in Healthy Volunteers
por: Rocha, José‐Francisco, et al.
Publicado: (2021) -
Bioequivalence of Eslicarbazepine Acetate from Two Different Sources of its Active Product Ingredient in Healthy Subjects
por: Falcão, Amílcar, et al.
Publicado: (2013) -
Preclinical pharmacological evaluation of the fatty acid amide hydrolase inhibitor BIA 10‐2474
por: Bonifácio, Maria‐João, et al.
Publicado: (2020) -
BIA-ALCL-Horizon Scanning
por: Mallucci, Patrick, et al.
Publicado: (2022)